AU647859B2 - Anti-atherosclerotic aryl compounds - Google Patents

Anti-atherosclerotic aryl compounds

Info

Publication number
AU647859B2
AU647859B2 AU90560/91A AU9056091A AU647859B2 AU 647859 B2 AU647859 B2 AU 647859B2 AU 90560/91 A AU90560/91 A AU 90560/91A AU 9056091 A AU9056091 A AU 9056091A AU 647859 B2 AU647859 B2 AU 647859B2
Authority
AU
Australia
Prior art keywords
alkyl
compound
formula
atoms
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU90560/91A
Other languages
English (en)
Other versions
AU9056091A (en
Inventor
James Mood Chapman
Karl Witold Franzmann
Roy Lee Hawke
Kevin Julian O'connor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Carolina
Original Assignee
Wellcome Foundation Ltd
University of South Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd, University of South Carolina filed Critical Wellcome Foundation Ltd
Publication of AU9056091A publication Critical patent/AU9056091A/en
Application granted granted Critical
Publication of AU647859B2 publication Critical patent/AU647859B2/en
Assigned to UNIVERSITY OF SOUTH CAROLINA reassignment UNIVERSITY OF SOUTH CAROLINA Alteration of Name(s) in Register under S187 Assignors: UNIVERSITY OF SOUTH CAROLINA, WELLCOME FOUNDATION LIMITED, THE
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Indole Compounds (AREA)
AU90560/91A 1990-12-12 1991-12-11 Anti-atherosclerotic aryl compounds Ceased AU647859B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9027023 1990-12-12
GB909027023A GB9027023D0 (en) 1990-12-12 1990-12-12 Anti-atherosclerotic aryl compounds
PCT/GB1991/002195 WO1992010468A1 (en) 1990-12-12 1991-12-11 Anti-atherosclerotic aryl compounds

Publications (2)

Publication Number Publication Date
AU9056091A AU9056091A (en) 1992-07-08
AU647859B2 true AU647859B2 (en) 1994-03-31

Family

ID=10686924

Family Applications (1)

Application Number Title Priority Date Filing Date
AU90560/91A Ceased AU647859B2 (en) 1990-12-12 1991-12-11 Anti-atherosclerotic aryl compounds

Country Status (16)

Country Link
US (1) US5658944A (enExample)
EP (1) EP0639178B1 (enExample)
JP (1) JP2951402B2 (enExample)
KR (1) KR930703246A (enExample)
AT (1) ATE157651T1 (enExample)
AU (1) AU647859B2 (enExample)
CA (1) CA2098122C (enExample)
DE (1) DE69127556D1 (enExample)
GB (1) GB9027023D0 (enExample)
HU (1) HUT64514A (enExample)
IE (1) IE914304A1 (enExample)
IL (1) IL100331A (enExample)
NZ (1) NZ240935A (enExample)
TW (1) TW275065B (enExample)
WO (1) WO1992010468A1 (enExample)
ZA (1) ZA919773B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4401893A1 (de) * 1994-01-24 1995-07-27 Bayer Ag Substituierte Arylharnstoffe
SE9401353D0 (sv) * 1994-04-21 1994-04-21 Pharmacia Ab Novel antitumour compounds with antimitotic activity
HRP950558A2 (en) * 1994-11-15 1997-12-31 Scott M. Wilhelm Substituted 4-biarylbutric or biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
DE4443891A1 (de) * 1994-12-09 1996-06-13 Bayer Ag Heterocyclisch substituierte Oxy-phenyl-(phenyl)glycinolamide
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US5866609A (en) * 1996-08-09 1999-02-02 Ss Pharmaceutical Co., Ltd. Substituted vinylurea derivatives and medicine containing the same
JP2002543194A (ja) * 1999-04-28 2002-12-17 ドクター・レディーズ・ラボラトリーズ・リミテッド 置換二環系ヘテロ環化合物、その製造方法、並びに抗肥満症及び抗高コレステロール血症剤としてのこれらの使用
EP1310494B1 (en) 2000-08-11 2012-01-25 Nippon Chemiphar Co., Ltd. PPAR (delta) ACTIVATORS
WO2002046176A1 (en) * 2000-12-05 2002-06-13 Nippon Chemiphar Co., Ltd. Ppar (peroxisome proliferator activated receptor) activators
EP1360172A1 (en) * 2001-02-15 2003-11-12 Pfizer Products Inc. Ppar agonists
CA2438492A1 (en) * 2001-02-15 2002-08-22 Pfizer Products Inc. Proliferative activator receptor (ppar) compounds
US6548538B2 (en) * 2001-05-22 2003-04-15 Bayer Aktiengesellschaft Propionic acid derivatives
US20030191144A1 (en) * 2001-06-12 2003-10-09 Active Pass Pharmaceuticals, Inc. Compounds, compositions and methods for modulating beta-amyloid production
WO2002100836A2 (en) * 2001-06-12 2002-12-19 Active Pass Pharmaceuticals, Inc. Compounds, compositions and methods for modulating beta-amyloid production
AU2002323776B2 (en) 2001-08-10 2008-07-31 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator-responsive receptor Delta
JP4276074B2 (ja) 2001-10-12 2009-06-10 日本ケミファ株式会社 ペルオキシソーム増殖剤応答性受容体δの活性化剤
US7015345B2 (en) * 2002-02-21 2006-03-21 Asahi Kasei Pharma Corporation Propionic acid derivatives
AU2003241579B9 (en) 2002-06-19 2009-07-30 Eli Lilly And Company Amide linker peroxisome proliferator activated receptor modulators
EP1388352A1 (en) 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment
PT1554240E (pt) 2002-10-21 2009-06-17 Janssen Pharmaceutica Nv Tetralinas e indanos substituídos e sua utilização
ATE425966T1 (de) * 2002-11-26 2009-04-15 Pfizer Prod Inc Durch phenyl subtituierten piperidinverbindungen zur verwendung als ppar-aktivatoren
CA2511970C (en) 2003-01-14 2012-06-26 Cytokinetics, Inc. Urea derivatives useful in the treatment of heart failure
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
BRPI0512193B8 (pt) 2004-06-17 2021-05-25 Cytokinetics Inc composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
ES2419007T3 (es) 2005-12-15 2013-08-19 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y procedimientos
US7718657B2 (en) 2005-12-16 2010-05-18 Cytokinetics, Inc. Certain indanyl urea modulators of the cardiac sarcomere
EP1962852B1 (en) 2005-12-19 2017-01-25 Cytokinetics, Inc. Compounds, compositions and methods
ZA200809148B (en) 2006-04-18 2010-01-27 Nippon Chemiphar Co Activating agent for peroxisome proliferator activated receptor delta
JP5474769B2 (ja) 2008-04-15 2014-04-16 日本ケミファ株式会社 ペルオキシソーム増殖剤活性化受容体の活性化剤
ES2571452T3 (es) 2012-01-10 2016-05-25 Lilly Co Eli Compuesto antagonista de leucotrieno B4
WO2013169648A1 (en) 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4397868A (en) * 1982-01-26 1983-08-09 American Cyanamid Company Method of treating atherosclerosis with trisubstituted ureas
US4623662A (en) * 1985-05-23 1986-11-18 American Cyanamid Company Antiatherosclerotic ureas and thioureas
AU638950B2 (en) * 1988-11-21 1993-07-15 Wellcome Foundation Limited, The Anti-antherosclerotic diaryl compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2614045A1 (de) * 1976-04-01 1977-10-06 Boehringer Mannheim Gmbh Neue phenoxyalkylcarbonsaeuren und verfahren zur herstellung derselben
US4387106A (en) * 1982-01-26 1983-06-07 American Cyanamid Company Method of treating atherosclerosis with di(aralkyl)ureas and di(aralkyl)thioureas
WO1988010113A1 (en) * 1987-06-15 1988-12-29 Iraj Lalezari Compound, composition and method for the reduction of lipids the modification of the affinity of hemoglobin for oxygen and the prevention of platelet aggregation
US4921997A (en) * 1988-06-15 1990-05-01 Montefiore Medical Center Method of synthesis and novel compounds for pharmaceutical uses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4397868A (en) * 1982-01-26 1983-08-09 American Cyanamid Company Method of treating atherosclerosis with trisubstituted ureas
US4623662A (en) * 1985-05-23 1986-11-18 American Cyanamid Company Antiatherosclerotic ureas and thioureas
AU638950B2 (en) * 1988-11-21 1993-07-15 Wellcome Foundation Limited, The Anti-antherosclerotic diaryl compounds

Also Published As

Publication number Publication date
JP2951402B2 (ja) 1999-09-20
HUT64514A (en) 1994-01-28
KR930703246A (ko) 1993-11-29
EP0639178B1 (en) 1997-09-03
CA2098122C (en) 2003-09-23
TW275065B (enExample) 1996-05-01
DE69127556D1 (de) 1997-10-09
HU9301709D0 (en) 1993-09-28
WO1992010468A1 (en) 1992-06-25
IL100331A (en) 1996-09-12
JPH06507151A (ja) 1994-08-11
IE914304A1 (en) 1992-06-17
IL100331A0 (en) 1992-09-06
ZA919773B (en) 1993-06-11
CA2098122A1 (en) 1992-06-13
GB9027023D0 (en) 1991-01-30
US5658944A (en) 1997-08-19
AU9056091A (en) 1992-07-08
NZ240935A (en) 1994-11-25
EP0639178A1 (en) 1995-02-22
ATE157651T1 (de) 1997-09-15

Similar Documents

Publication Publication Date Title
AU9056091A (en) Anti-atherosclerotic aryl compounds
EP1446115B1 (en) Cyanoalkylamino derivatives as protease inhibitors
WO1991001306A1 (en) Oxoindole derivative
KR880000204B1 (ko) 설포닐 우레아 유도체
EA019882B1 (ru) Модуляторы рецептора простациклина (pgi2), пригодные для лечения связанных с ним расстройств
CN1246119A (zh) 吡咯并[3,4-d]-嘧啶酮衍生物及其作为药物的用途
RU2159228C2 (ru) Производные замещенного бензамидина
CN113226296A (zh) Ssao抑制剂及其用途
EA032314B1 (ru) Трициклические гетероциклические соединения, применимые в качестве ингибиторов tnf
PL154186B1 (en) Method for manufacturing arylic derivatives of the hydroxamic acid
EP3455212B1 (en) Inhibitors of protease-activated receptor-2
US4988682A (en) Myo-inositol analogs and method for their use
WO2016079669A1 (en) Labeled amino pyrimidine derivatives
US5422373A (en) Anti-atherosclerotic aryl compounds
FR2534582A1 (fr) Nouveaux derives de benzofuranne et de benzothiophene, utiles comme agents anti-hyperuricemie et anti-hypertension, et leur procede de fabrication
EP2324015B1 (fr) Derives de thiophene-2-carboxamide, leur preparation et leur application en therapeutique
FR2483232A1 (fr) Nouveaux agents anti-rhinovirus et leur procede de preparation
US5053399A (en) Myo-inositol analogs and methods for their use
CN103193695B (zh) 3-苯基-3-吡咯基戊烷类衍生物及其医药用途
FR2763847A1 (fr) Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
LU83827A1 (fr) Nouveaux composes heterocycliques azotes anti-inflammatoires et immunoregulateurs et composition pharmaceutique les contenant
BE1000783A3 (fr) Derives du 1,3-dioxolanne et du 1,3-dioxanne et leur utilisation comme medicaments.
EP0189080A2 (en) (1,2,4-Oxadiazol-3-YL)-arylmethanones, a process for their preparation and their use as medicaments
KR880001754B1 (ko) 에테르류 화합물의 제조방법
TW202604893A (zh) 經取代吡啶及苯基化合物